Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...

Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New England Journal of Medicine, suggest that ...

Moderna has filed a lawsuit against Pfizer and its German partner BioNTech for allegedly copying their COVID-19 vaccine. On Friday, Moderna issued a news release accusing Pfizer of infringing several ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Pfizer’s mRNA flu shot prevented more flu-like illness than a standard vaccine More than 18,000 adults took part in the study Side effects were mild and went away quickly FRIDAY, Nov. 21, 2025 ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. recently terminated $500 million in federal funding for developing mRNA vaccines, but don’t be fooled into thinking these life-saving ...

WASHINGTON, DC: Jayanta Bhattacharya, Director of the National Institutes of Health. (Photo by Andrew Harnik/Getty Images) Director of the National Institutes of Health, Jay Bhattacharya, recently ...

When the Pfizer-BioNTech COVID-19 vaccine was authorized for emergency use by the Food and Drug Administration (FDA) in December 2020, President Donald Trump referred to it as a "medical miracle." ...

The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...